News Mar 22, 2026
Porton and Jianxiang Forge Strategic Partnership to Build a New High Ground for Large-scale Peptide Drug Manufacturing
Porton and Jianxiang partner to deliver integrated peptide CDMO services from development to commercial manufacturing, offering scalable, compliant solutions for global clients.
News Mar 03, 2026
Porton Wins “2025 Best CRO” Award from Daewoong Pharma
Daewoong Pharma highly recognized Porton’s contributions to its drug development through active cooperation based on Porton’s excellent capabilities and expertise.
NewslettersFeb 03, 2026
Porton Newsletter - January 2026 Recap
Porton Newsletter - January 2026 Recap
NewslettersJan 09, 2026
Porton Newsletter - Q4 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities Others
News Jan 08, 2026
A Porton Publication in ACS Journal on Polymorphic Crystallization Kinetics Study and Control
Porton's new study in ACS journal explores methodology for designing processes to isolate pure metastable API polymorphs using crystallization kinetics.
News Dec 30, 2025
Porton Achieves EU QP Certification for Chongqing Manufacturing Facility
Porton Pharma's Chongqing facility successfully completes EU QP Audit. Third site to meet European quality standards for drug manufacturing.
News Dec 23, 2025
Porton&Nona: Strategic Partnership for Complex Antibody Therapy
Global biotech Nona partners with CDMO Porton to accelerate complex antibody drug development and commercialization.
NewslettersDec 12, 2025
Porton Newsletter - November 2025 Recap
Technical Enabling Services & Solutions Company Events ESG Marketing Activities Others
News Nov 27, 2025
Porton Pharma Solutions Ranks Among China's Top 100 Premier Pharmaceutical Suppliers and Top 10 in ESG Competitiveness
Porton ranked among China's Top 100 Pharmaceutical Suppliers & ESG Competitiveness Top 10, offering global CDMO services & sustainable solutions.
